Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Spruce Biosciences Inc (SPRB)
Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,503
  • Shares Outstanding, K 40,711
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,180 K
  • 60-Month Beta 2.58
  • Price/Sales 25.84
  • Price/Cash Flow N/A
  • Price/Book 2.56
Trade SPRB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.50
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +12.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.44 +125.00%
on 01/25/24
5.60 -1.96%
on 02/23/24
+2.97 (+117.86%)
since 01/23/24
3-Month
1.32 +315.91%
on 11/27/23
5.60 -1.96%
on 02/23/24
+4.13 (+303.68%)
since 11/22/23
52-Week
1.01 +443.56%
on 11/15/23
5.60 -1.96%
on 02/23/24
+3.16 (+135.62%)
since 02/23/23

Most Recent Stories

More News
S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook

September S&P 500 futures (ESU23) are trending up +0.08% this morning after the S&P 500 and Nasdaq closed in the red on Thursday as technology stocks dropped on concerns over the outlook for Apple, while...

ESU23 : 4,491.72s (-0.32%)
AAPL : 182.52 (-1.00%)
SWKS : 103.85 (-1.03%)
QCOM : 154.91 (+0.10%)
AI : 26.15 (-1.80%)
INTC : 42.99 (+0.02%)
MCD : 297.75 (+0.62%)
CCC.LN : 2,940.000 (+0.82%)
DOCU : 51.73 (+3.17%)
ADBE : 553.44 (+2.95%)
SMAR : 42.04 (+0.02%)
SWBI : 13.62 (-0.29%)
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)
Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know

Spruce Biosciences, Inc. (SPRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SPRB : 5.49 (+2.43%)
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)
Spruce Biosciences Announces $53.6 Million Private Placement Financing

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

SPRB : 5.49 (+2.43%)
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 5.49 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

See More

Key Turning Points

3rd Resistance Point 6.07
2nd Resistance Point 5.84
1st Resistance Point 5.66
Last Price 5.49
1st Support Level 5.25
2nd Support Level 5.02
3rd Support Level 4.84

See More

52-Week High 5.60
Last Price 5.49
Fibonacci 61.8% 3.85
Fibonacci 50% 3.30
Fibonacci 38.2% 2.76
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar